Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

al uses of such tool. The forward-looking statements are usually (but not always) identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning.  Actual results could differ materially from the expectations contained in forward-looking statements as a result of risks and uncertainties including clinical trial enrollment and results, regulatory approval requirements, unexpected expenditures and costs, unexpected results or delays in development and regulatory review, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2013. Halozyme does not undertake to update these forward-looking statements.

References
1. American Cancer Society, Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013
2. Pancreatic Cancer, American Cancer Society, http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-key-statistics  Accessed April 18, 2013

 

Investor Contact:
Kurt Gustafson
Halozyme Therapeutics
858-704-8272
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill+Knowlton Strategies
310-633-9434
Nurha.Hindi@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 05, 2015 e2b teknologies , ... located in Northeast Ohio, today announced a leading independent ... support its upgrade to the latest version of ... group practice of its kind in the region, the ... of transactions, so efficiency and data accessibility are paramount ...
(Date:3/5/2015)... Texas (PRWEB) March 05, 2015 ... of acute and chronic orthopedic conditions such as ... knee, tennis elbow, and joint pain due to ... be administered during orthopedic surgeries to promote better ... scientific advances in nearly pain-free bone marrow harvesting ...
(Date:3/4/2015)... 4, 2015 In an article published and ... for Health Security review the clinical aspects of diseases ... as bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related ... website of the New England Journal of Medicine ... Toner , and Tom Inglesby—review the clinical management of ...
(Date:3/4/2015)... March 4, 2015  Brooklyn residents now have a ... chronic pain and injuries. Nunzio Saulle , M.D., ... opening of his NJS Physical Medicine and Rehabilitation (PM&R) ... Thursday, March 5, 2015. Health Plus Management, LLC is ... located at 1178 Flatbush Avenue. This new PM&R practice ...
Breaking Biology Technology:Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5Latest Clinical Information On Bioterrorism Threats 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
... 13 Proteon,Therapeutics, Inc. ( http://www.proteontherapeutics.com ), announced ... the European Patent Office. The patent,(No. 1220830) covers ... as elastases for,dilating arteries and veins in humans. ... in June and December of 2006. Proteon Therapeutics,owns ...
... has received its second Frost & Sullivan Technology Award ... the Frost & Sullivan Awards Banquet,Signalife was awarded the ... Monitoring. Signalife,s Chief Executive Officer, Dr.,Lowell Harmison, and its ... accept the award., Signalife, Inc. is in a ...
... Advancing Lead Candidate HspE7 into Phase 2 Clinical Trial in ... ... 13 Nventa Biopharmaceuticals,Corporation announced today financial results for the year ended ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO ), During 2007, the Company achieved ...
Cached Biology Technology:Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins 2Signalife Wins Second Frost & Sullivan Technology Award 2Signalife Wins Second Frost & Sullivan Technology Award 3Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 3Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 4Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 5Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 6Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 7
(Date:2/5/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... Online CEO Conference on January 29 th at ... , CEO of NXT-ID will present and host a ... smart wallet and its full suite of biometric technologies. ...
(Date:2/5/2015)...  It is gratifying to see that the Obama ... science as a means to better understand human biology, ... was honored to participate in today,s White House event ... Since the 1980s my teams have been ... sequenced genome of a free living organism, the first ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... Shenzhen, China The Asian Cancer Research Group ... and Company, Merck (known as MSD outside the ... with BGIthe world,s largest genomics organizationtoday announced the ... of recurrent hepatitis B virus (HBV) integration in ...
... researchers have known for well over a century that different ... one has been able to determine the mechanisms of organ ... New details that could help shed light on this hypothesis ... Cornell Medical College, Memorial Sloan-Kettering Cancer Center, and their collaborators, ...
... new study, children exposed to high levels of the ... chromosomal aberrations (CAs), which have been previously associated with ... and long-lasting subtype of CAs. Researchers from the ... Mailman School of Public Health, Columbia University Medical Center, ...
Cached Biology News:ACRG and BGI report findings from genomics research on recurrent hepatitis B virus integration 2ACRG and BGI report findings from genomics research on recurrent hepatitis B virus integration 3Cancerous tumors deliver pro-metastatic information in secreted vesicles 2Cancerous tumors deliver pro-metastatic information in secreted vesicles 3Cancerous tumors deliver pro-metastatic information in secreted vesicles 4Children exposed to the common pollutant naphthalene show signs of chromosomal damage 2Children exposed to the common pollutant naphthalene show signs of chromosomal damage 3
Request Info...
Special grade: for electrophoresis...
This device is designed to run four simultaneous separations with the following StemSep ; column sizes: 0.3in., 0.5in., and 0.6in.. Depending on the column size, a range of 2x10 7 - 1.5 x 10 9 cell...
... (CYP450) metabolite postulated to play an autacoid ... In rat cerebral microvessels, 20-HETE is a ... is excreted mainly as the glucuronide conjugate. ... in human urine) is about 10-fold lower ...
Biology Products: